REGENXBIO’s Gene Therapies: Ready For Prime Time?
This article was originally published in Start Up
Executive Summary
Five-year-old REGENXBIO has successfully licensed its vector technology to nine partners, who have reaped $300 million in the process.
You may also be interested in...
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.